Invex Therapeutics (ASX:IXC) — Material Events
ASX:IXC · 13 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Invex Therapeutics Resumes Trading After Major Acquisition RevealHigh
Invex Therapeutics Ltd reinstated to trading after material acquisition announcement
30 Sept 2025
·Reinstatement to Quotation
·Unexpected
·85
Invex Therapeutics Halts Two Neurological Deals Amid Board TurmoilHigh
Invex Therapeutics ends two neurological asset deals, continues R&D, faces board challenges
3 Oct 2025
·Quarterly Activities Report & Appendix 4C
·Unexpected
·75
Invex Therapeutics Halts Acquisition Talks Amid Boardroom TurmoilMedium
Invex Therapeutics discloses ended acquisition talks amid ASX price query
30 Sept 2025
·ASX Query Response
·Unexpected
·70
Invex Therapeutics Advances Alzheimer’s Research Amid Board Shakeup and $4.5M Cash ReserveMedium
Invex Therapeutics advances Alzheimer's research collaboration, announces board changes and reports $4.5M cash at quarter end
22 Jan 2026
·Quarterly Activities Report & Appendix 4C
·70
Invex Therapeutics Doubles Half-Year Loss Amid Progress in Alzheimer’s Drug ResearchMedium
Invex Therapeutics reports increased half-year loss, advances Exenatide research, and announces board changes
12 Feb 2026
·Half-Year Financial Report
·70
Invex Therapeutics Halts Trading Ahead of Major Acquisition RevealMedium
Invex Therapeutics requests voluntary trading suspension pending material acquisition announcement
25 Sept 2025
·Voluntary Suspension Request
·70
Invex Therapeutics Halts Acquisition Amid Boardroom TurmoilMedium
Invex Therapeutics halts acquisition talks amid board removal dispute, maintains diversification strategy
30 Sept 2025
·Corporate Update
·Unexpected
·70
Invex Therapeutics Suspended from ASX Over Board ShortfallHigh
Invex Therapeutics Ltd suspended from ASX for insufficient directors
7 Nov 2025
·Suspension from Quotation
·Unexpected
·70
Invex Therapeutics Advances Exenatide Research with New Alzheimer’s Model DataMedium
Invex Therapeutics advances Exenatide research in Alzheimer's model; Q3 cash at $4.5M with lower operating outflows
24 Apr 2026
·Quarterly Activities Report & Appendix 4C
·60
Invex Therapeutics Reports $1.35M Loss as Alzheimer’s Research IntensifiesMedium
Invex Therapeutics reports $1.35M loss for FY2026 driven by R&D expansion and collaboration with Tessara Therapeutics
31 Aug 2026
·Preliminary Final Report
·60
Invex Therapeutics Expands Alzheimer’s Research Amid Rising R&D Spend and $4M Cash ReserveMedium
Invex Therapeutics expands Alzheimer's preclinical research; Q4 FY26 cash falls to $4.02M with higher R&D spend
23 July 2026
·Quarterly Activities Report and Appendix 4C
·50
Invex Therapeutics Resumes Trading After Key Board AppointmentsMedium
Invex Therapeutics Ltd reinstated to trading after board and officer appointments announcement
10 Nov 2025
·Reinstatement to Quotation
·50
Invex Therapeutics Refreshes Board and Leadership Amid Strategic ResetMedium
Invex Therapeutics appoints new directors and company secretaries; updates company address
10 Nov 2025
·Board and Officer Appointment
·50
No articles in this tier for the last 12 months.
Market Mentions
4
- appeared in market wrap coverage
These are market wrap articles where Invex Therapeutics (ASX:IXC) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Healthcare Wrap - Week 7 (9 Feb -> 13 Feb) 2026
14 Feb 2026
Healthcare Wrap - Week 4 (19 Jan -> 23 Jan) 2026
25 Jan 2026